scholarly journals Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6239
Author(s):  
Joan Tymon-Rosario ◽  
Naomi N. Adjei ◽  
Dana M. Roque ◽  
Alessandro D. Santin
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
Standard Of Care ◽  
Therapeutic Agents ◽  
Chemotherapeutic Agents ◽  
Front Line ◽  
Current Standard ◽  
The Past ◽  
Taxane Resistance

Taxanes and epothilones are chemotherapeutic agents that ultimately lead to cell death through inhibition of normal microtubular function. This review summarizes the literature demonstrating their current use and potential promise as therapeutic agents in the treatment of epithelial ovarian cancer (EOC), as well as putative mechanisms of resistance. Historically, taxanes have become the standard of care in the front-line and recurrent treatment of epithelial ovarian cancer. In the past few years, epothilones (i.e., ixabepilone) have become of interest as they may retain activity in taxane-treated patients since they harbor several features that may overcome mechanisms of taxane resistance. Clinical data now support the use of ixabepilone in the treatment of platinum-resistant or refractory ovarian cancer. Clinical data strongly support the use of microtubule-interfering drugs alone or in combination in the treatment of epithelial ovarian cancer. Ongoing clinical trials will shed further light into the potential of making these drugs part of current standard practice.

A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future

2012 ◽  
pp. 28-38 ◽  
Author(s):  
George W. Sledge ◽  
Fatima Cardoso ◽  
Eric P. Winer ◽  
Martine J. Piccart
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Scientific Discovery ◽  
Metastatic Breast ◽  
Standard Of Care ◽  
Chemotherapeutic Agents ◽  
Targeted Therapeutics ◽  
Current Standard ◽  
The Past ◽  
Incurable Disease

Overview: Metastatic breast cancer (MBC), a usually incurable disease, continues to vex physicians and patients. Recent decades have seen great improvements in the treatment of MBC, based on the availability of novel targeted therapeutics and more standard chemotherapeutic agents. This article describes the goals of therapy for MBC, the progress made against MBC in recent decades, the current standard of care, and the ongoing efforts of basic and translational researchers to transfer the fruits of modern scientific discovery to patients in the clinic.

scholarly journals Systemic Treatment of Stage IV Epithelial Ovarian Cancer; A Case Report

2020 ◽  
Vol 10 (2) ◽  
Author(s):  
Shoukat Ali
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Systemic Chemotherapy ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Stage Iv ◽  
Standard Of Care ◽  
Parp Inhibitors ◽  
Gynecologic Malignancy ◽  
Current Standard

Epithelial ovarian cancer is most common gynecologic malignancy in Pakistan. Primary cytoreductive surgery followed by adjuvant chemotherapy is current standard of care for most of the patients with epithelial ovarian cancer, however neoadjuvant chemotherapy followed by surgery is acceptable alternate option for patients presenting with inoperable advanced disease initially. For most of the stage IV ovarian cancer patients, systemic chemotherapy is mainstay of treatment, but other approaches have been emerged for advanced disease including targeted agents, hormonal therapy and PARP inhibitors.

Systemic treatment policies in ovarian cancer: the next 10 years

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 231-240 ◽  
Author(s):  
J. J. Biagi ◽  
E. A. Eisenhauer
Keyword(s):  
Ovarian Cancer ◽  
Systemic Treatment ◽  
Standard Of Care ◽  
Standards Of Care ◽  
Front Line ◽  
The Past ◽  
Line Therapy ◽  
Randomized Studies ◽  
Treatment Policies ◽  
Contradictory Data

Over the past two decades, the development of treatment policies and practice standards has become formalized. In ovarian cancer, most attention has been focused on the development of policies for front-line systemic treatment, using survival as the major outcome that should drive change. This review summarizes the evidence that supported the emergence of paclitaxel–carboplatin as a widely used standard of care for front-line therapy and some of the contradictory data from randomized studies. Furthermore, recently completed or ongoing randomized studies of the addition of a third cytotoxic agent to paclitaxel–carboplatin are summarized. Finally, some novel noncytotoxic approaches are discussed. New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned.

scholarly journals Glioblastoma Multiforme—A Look at the Past and a Glance at the Future

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1053
Author(s):  
Jasmine L. King ◽  
Soumya Rahima Benhabbour
Keyword(s):  
Glioblastoma Multiforme ◽  
Immune Surveillance ◽  
Standard Of Care ◽  
Current Standard ◽  
Comprehensive Overview ◽  
Therapeutic Delivery ◽  
The Past ◽  
Adults And Children ◽  
The Central Nervous System ◽  
Delivery Strategies

Gliomas are the most common type of brain tumor that occur in adults and children. Glioblastoma multiforme (GBM) is the most common, aggressive form of brain cancer in adults and is universally fatal. The current standard-of-care options for GBM include surgical resection, radiotherapy, and concomitant and/or adjuvant chemotherapy. One of the major challenges that impedes success of chemotherapy is the presence of the blood–brain barrier (BBB). Because of the tightly regulated BBB, immune surveillance in the central nervous system (CNS) is poor, contributing to unregulated glioma cell growth. This review gives a comprehensive overview of the latest advances in treatment of GBM with emphasis on the significant advances in immunotherapy and novel therapeutic delivery strategies to enhance treatment for GBM.

scholarly journals Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

2020 ◽  
Author(s):  
Yan Rong ◽  
Li Li
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
First Line ◽  
Clinical Value ◽  
Platinum Sensitivity ◽  
Platinum Sensitive ◽  
Platinum Resistant ◽  
Line Chemotherapy ◽  
Sensitive Group

Abstract Objectives: To assess the clinical value of early clearance of HE4 and CA125 for platinum sensitivity and prognosis in patients with ovarian cancer.Method: HE4 and CA125 value including clinical data of 89 patients with ovarian cancer were collected. The clearance of HE4 and CA125 were assessed base on the platinum sensitivity, two-year PFS, PFS and OS.Results: 16 patients were classified as platinum resistant and 73 as platinum sensitive according to the response to platinum-base chemotherapy. When HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle chemotherapy, it gave the highest AUC of 0.788, with 100% of sensitivity and 57.5% of specificity respectively between platinum resistant and platinum sensitive group. In addition, 59 patients were classified as two-year PFS group and 30 as not achieved two-year PFS group according to obtaining two-year PFS or not. It gave the highest AUC of 0.730, with 83.3% of sensitivity and 62.7% of specificity respectively when HE4 clearance after 3rd cycle chemotherapy or CA125 clearance after 1st cycle. The prolonged PFS and OS were significantly associated by the clearance of HE4 after 3rd cycle chemotherapy (p<0.0001, p<0.0001) as well as CA125 after 1st cycle chemotherapy (p<0.0001, p<0.0001).Conclusions: Our data suggested that the early clearance of HE4 and CA125 could predict platinum response and prognosis in patients with ovarian cancer. Monitoring the HE4 and CA125 during first-line chemotherapy might be helpful in predicting platinum sensitivity and risk to progress and relapse.

A Mother in Jeopardy: The Ethics of Pregnancy and Chemotherapy

2019 ◽  
Vol 37 (1) ◽  
pp. 72-78
Author(s):  
Steven J. Baumrucker ◽  
Wendy H. Vogel ◽  
Robert M. Stolick ◽  
Russell W. Adkins ◽  
Heather Holland ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Cyst ◽  
Peritoneal Fluid ◽  
Polycystic Ovary ◽  
Advanced Stage ◽  
Ovarian Mass ◽  
Prenatal Visit ◽  
The Past ◽  
Fluid Cytology

JM is a 32-year-old primagravida with polycystic ovary disease. She had extreme difficulty conceiving and was started on clomiphene 6 months ago by her fertility specialist. After doubling the dose on the sixth cycle, she successfully became pregnant. On her second prenatal visit at 12 weeks gestation, an ovarian cyst was detected. Ultrasound showed a complex ovarian mass with nodules on the bowel and abdominal wall. There was mild-to-moderate peritoneal fluid. Cytology showed adenocarcinoma of ovarian origin. Further workup demonstrated advanced stage III epithelial ovarian cancer. JM was referred to GYN-oncology who felt pregnancy-sparing debulking was not an option. The oncologist recommended termination of pregnancy due to the risks of delaying chemotherapy. JM refused, citing her fertility difficulties in the past and her desire to carry the pregnancy to term “even if it kills me.” She tells the oncologist she cannot bear the thought of terminating her pregnancy under any circumstances. The oncologist wants to comply with her wishes but feels the patient is making a choice that would result in harm to herself. The oncology team requests an ethics consult.

scholarly journals Immunotherapy Advances for Epithelial Ovarian Cancer

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3733
Author(s):  
Erin G. Hartnett ◽  
Julia Knight ◽  
Mackenzy Radolec ◽  
Ronald J. Buckanovich ◽  
Robert P. Edwards ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Cancer ◽  
Single Agent ◽  
Standard Of Care ◽  
Treatment Modalities ◽  
Cancer Type ◽  
Immune Effector ◽  
Effector Cells ◽  
Immune Therapies

New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials.

scholarly journals Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer

2018 ◽  
Vol 14 ◽  
pp. 174550571775069 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Drug Administration ◽  
Clinical Data ◽  
Food And Drug Administration ◽  
Gynecologic Oncology ◽  
Brca Gene ◽  
Polymerase Inhibitors ◽  
The Us ◽  
Relevant Role

There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and particularly (although not exclusively) in the setting of known mutations in the BRCA gene. This review will briefly highlight the biological rational for the use of poly (ADP-ribose) polymerase inhibitors in this malignancy, followed by summary of currently available clinical data supporting the delivery of agents approved by the US Food and Drug Administration for non-investigative use.

Sign in / Sign up

Export Citation Format

Share Document